COPD Care in the 21st Century: A Public Health Priority
- PMID: 29692353
- PMCID: PMC6373864
- DOI: 10.4187/respcare.06276
COPD Care in the 21st Century: A Public Health Priority
Abstract
COPD is an underdiagnosed, undertreated, and yet largely preventable disease. COPD affects millions of Americans on a daily basis, accounts for tens of thousands of deaths per year, and costs billions to the United States health-care system annually. Further, it impacts the quality of life for patients living with the disease. COPD care is fragmented in the United States, with a high level of responsibility placed on patients and their primary care physicians. Pulmonary specialists care for a minority of patients with COPD in the United States. Unfortunately, tobacco dependence, which is the leading cause of COPD, remains prevalent. Further, women and those with low socioeconomic status continue to share a relatively greater burden of disease. Exacerbations are experienced frequently by patients and contribute to high rates of emergency department visits and in-patient admissions and readmissions as well as high medical costs to the United States economy. Numerous strategies have been proposed to combat these high rates, including the use of discharge bundles, hospital at-home programs, telemedicine, and tele-rehabilitation, but no single best strategy has emerged. The COPD National Action Plan was introduced in 2017 as part of a multi-stakeholder endeavor to encourage collaboration among various patients, caregivers, physicians, researchers, and policymakers to optimize awareness, diagnosis, and treatment of this disease. It is time to make COPD care a public health priority.
Keywords: COPD; COPD exacerbation; discharge bundle; disparities; economic burden; primary care physician; readmission; tele-rehabilitation; telemedicine; tobacco cessation.
Copyright © 2018 by Daedalus Enterprises.
Conflict of interest statement
Dr Criner has disclosed no conflicts of interest. Dr. Han has disclosed relationships with Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Sunovion, and Novartis.
Figures
References
-
- Kochanek KD, Murphy SL, Xu J, Arias E. Mortality in the United States, 2016. Atlanta, Georgia: Centers for Disease Control and Prevention; 2017.
-
- Ford ES, Mannino DM, Wheaton AG, Giles WH, Presley-Cantrell L, Croft JB. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010. Chest 2013;143(5):1395–1406. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
